<DOC>
	<DOCNO>NCT00020943</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy rituximab peripheral stem cell transplantation treat patient mantle cell lymphoma .</brief_summary>
	<brief_title>Chemotherapy Rituximab With Peripheral Stem Cell Transplantation Treating Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine two-year progression-free survival patient mantle cell lymphoma treat intensive chemotherapy rituximab autologous peripheral blood stem cell ( PBSC ) transplantation . - Determine complete partial response rate patient treated regimen . - Determine disease-free overall survival patient treat regimen . - Determine autologous immune reconstitution patient treat regimen . - Determine feasibility regimen patient population . - Determine whether treatment rituximab autologous PBSC transplantation reduces amount contaminate lymphoma autologous PBSC product . OUTLINE : This multicenter study . Patients receive induction therapy comprise rituximab IV 4-6 hour day 1 ; methotrexate IV 4 hour day 2 ; cyclophosphamide IV 2 hour , doxorubicin IV , vincristine IV day 3 ; oral prednisone day 3-7 . Patients also receive leucovorin calcium IV every 6 hour begin day 3 continue blood level methotrexate safe . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) begin day 4 continue blood count recover . Induction therapy repeat every 21-28 day 2 course absence disease progression unacceptable toxicity . Rituximab may omit course 1 circulate mantle cell excessive . Patients may receive third course 15 % persistent bone marrow involvement document . Patients stable respond disease begin consolidation therapy 29 day start final course induction therapy . Patients receive cytarabine IV 2 hour twice daily etoposide IV 96 hour day 1-4 . Patients also receive rituximab IV 4-6 hour day 5 6 12 13 G-CSF SC begin day 14 continue leukapheresis complete . Patients undergo leukapheresis begin day 22-25 continue adequate CD34 cell collect . Beginning 4 week recovery consolidation therapy , patient receive high-dose therapy comprise carmustine IV 2 hour day -6 , etoposide IV 4 hour day -4 , cyclophosphamide IV 2 hour day -2 . Patients undergo autologous peripheral blood stem cell ( PBSC ) transplantation day 0 . Patients receive G-CSF SC begin day 6 continue blood count recover . After blood count recover 35 day autologous PBSC transplantation , patient receive rituximab IV 4-6 hour weekly 2 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually 10 year . PROJECTED ACCRUAL : At least 45 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma Presenting least one following : Coexpression CD20 ( CD19 ) CD5 lack CD23 expression immunophenotyping Positive cyclin D1 immunostaining Presence ( 11,14 ) cytogenetic analysis Molecular evidence bcl1/IgH rearrangement Stage IIV disease Stage III IV nodular histology mantle cell lymphoma present Any stage mantle cell histologies No mantle zone histology No active CNS disease No symptomatic meningeal lymphoma No known CNS parenchymal lymphoma Lumbar puncture show mantle cell lymphoma allow Bidimensionally measurable disease great 1 cm Nonmeasurable disease include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Lesions previously irradiate area PATIENT CHARACTERISTICS : Age : 18 69 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Hepatitis B surface antigen hepatitis C antibody positive patient must meet following criterion : Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN Liver biopsy show great grade 2 fibrosis cirrhosis Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF least 45 % MUGA echocardiogram Other : No known hypersensitivity murine product HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior dose rituximab Chemotherapy : No 1 prior cycle chemotherapy At least 3 week since prior chemotherapy No concurrent chemotherapeutic agent Endocrine therapy : No chronic use oral corticosteroid ongoing medical condition No concurrent hormonal therapy except nonlymphomarelated condition ( e.g. , insulin diabetes ) Other concurrent corticosteroid adrenal failure , diffuse alveolar hemorrhage , carmustine pneumonitis , antiemetic allow Radiotherapy : No prior radiotherapy mantle cell lymphoma Concurrent palliative radiotherapy allow Concurrent cranial radiotherapy asymptomatic meningeal lymphoma allow Surgery : At least 2 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>